Global Clinical Lead, Pfizer Research and DevelopmentPfizer IncCollegeville, Pennsylvania, United States
OC 30.5 - Efficacy and safety of fidanacogene elaparvovec in adults with moderately severe or severe hemophilia B: updated results from the phase 3 BENEGENE-2 gene therapy trial
Monday, June 24, 202410:30 – 10:45 ICT
